- **Revenue and Profitability**: Q2 net revenue $68.1M (+64% YoY), first quarterly net income $9.7M, and full-year guidance raised to $265M-$275M.
- **Patient Growth**: 3,100 active patients (+63% YoY), with 64% YoY revenue growth and 63% new patient starts YoY.
- **IH Expansion**: Phase III IH trial nearing completion, targeting 2026 data readout for 42,000 IH patients (11% treated).
- **Litigation Strength**: Court affirmed LUMRYZ's superiority; antitrust trial seeks >$1B recovery.
- **Operational Efficiency**: 30% sequential revenue growth, 32% gross profit growth, and $15M cash generation.

**【CEO Opening Remarks】**
- **Patient Growth**: 3,100 active patients on LUMRYZ as of Q2, up 63% YoY, with 64% YoY revenue growth to $68.1M.
- **Financial Milestones**: First quarterly net income of $9.7M ($0.10 EPS) and cash generation of $15M.
- **Guidance Update**: Full-year 2025 revenue raised to $265M-$275M, driven by commercial execution and IH expansion.
- **Litigation Progress**: Court affirmed LUMRYZ's clinical superiority; antitrust trial set for Nov 2025 with potential recovery >$1B.
- **IH Pipeline**: Phase III REVITALYZ trial nearing completion, targeting 2026 data readout for IH indication.

**【COO Commercial Update】**
- **Prescriber Adoption**: 80% of new prescribers continue prescribing LUMRYZ, with 94% of switch patients preferring LUMRYZ in Phase III extension.
- **Patient Metrics**: Improved persistency, reimbursement rates, and patient mix (over 50% switch patients).
- **Investments**: Expanded sales force to 60 reps and direct-to-patient programs to accelerate growth.
- **Market Expansion**: LUMRYZ positioned to address IH's 42,000 diagnosed patients (11% treated) with once-nightly dosing.

**【CFO Financial Commentary】**
- **Revenue**: Q2 net revenue $68.1M (+64% YoY), with Q3 guidance of $71M-$75M (+46% YoY).
- **Profitability**: Adjusted operating income $15M, gross profit $61.8M, and cash operating expenses $46.8M.
- **Cash Flow**: $81.5M cash on hand, supporting commercial and clinical initiatives.
- **Cost Structure**: Highly leveraged model with 30% sequential revenue growth and 32% gross profit growth.

**【Q&A Highlights】**
- **Patient Mix**: Over 50% switch patients, with improving persistency and reimbursement rates.
- **Pricing**: Annualized net revenue per patient ~$92,000, driven by gross-to-net improvements.
- **Market Growth**: Oxybate market expanding due to LUMRYZ's simplified dosing, attracting new prescribers.
- **Litigation Strategy**: Focused on defending intellectual property and pursuing antitrust recovery.


Avadel Pharmaceuticals (AVDL)-7 Aug 25-2025 Q2 Earnings call transcript

- **Revenue & Patient Growth**: Q1 2025 narcolepsy revenue up 90% YoY to $52.5M, patients on therapy doubled to 2,800. IH court win unlocks $250M+ market opportunity.\n- **Strategic Wins**: Federal Circuit overturns injunction, enabling IH NDA pursuit. Antitrust trial vs Jazz seeks >$1B.\n- **Financial Momentum**: Full-year 2025 revenue guidance raised to $255-265M. 3rd consecutive quarter of positive adjusted operating income ($2M).\n- **Operational Excellence**: 50% Q1 net new patient growth vs Q4, driven by 15% sales force expansion and doubled field teams.\n- **Long-Term Vision**: Targeting $1B narcolepsy revenue, expanding to IH and other hypersomnia disorders with once-nightly oxybate platform.

**【CEO Summary Section】**
- **LUMRYZ Narcolepsy Franchise Growth**: Q1 2025 net revenue of $52.5M, up 90% YoY. Patients on therapy reached 2,800 (100% YoY growth). Q1 net new patients increased 50% vs Q4 2024, driven by expanded sales force (+15%), doubled field reimbursement and nursing teams.\n- **IH Expansion Win**: Federal Circuit overturned injunction, enabling FDA approval pursuit for LUMRYZ in IH. IH market potential: ~42,000 diagnosed patients with only 10% treated.\n- **Pipeline & Litigation**: Phase 3 IH trial on track for 2026 NDA. Filed offensive patent suits against Jazz for IH label infringement. Antitrust trial vs Jazz (Nov 2025) seeks >$1B recovery.\n- **Long-Term Vision**: Targeting $1B narcolepsy revenue, expanding to IH and other hypersomnia disorders.\n
**【CFO Financial Commentary】**
- **Q1 2025 Results**: Net revenue $52.5M, gross profit $46.9M. GAAP operating loss $3M, adjusted operating income $2M (3rd consecutive quarter positive).\n- **Guidance Update**: Full-year 2025 net revenue raised to $255-265M (prev $240-260M). Patients on therapy guidance increased to 3,400-3,600 (prev 3,300-3,500). Q2 2025 net revenue expected $60-63M.\n- **Financial Leverage**: >$30M cash flow expected for 2025. Non-cash royalty expense ($1.8M Q1) to be appealed. US-based manufacturing mitigates tariff risk.\n
**【Q&A Highlights】**
- **Patient Mix & Persistency**: Q1 switch patient growth outpaced new-to-oxybate. Discontinuation rate <14% (down from Q4). Expanded nursing support improved 90-day persistency.\n- **IH Market Dynamics**: Competitor IH product launch shows ~10% of IH diagnosed patients treated. LUMRYZ's once-nightly dosing differentiates from twice-nightly competitors.\n- **Generic Risk**: 2026 generic entry unlikely to impact LUMRYZ due to REMS requirements and focus on switch patients.\n- **Litigation Update**: Delaware court to rule on royalty rate appeal. Federal Circuit remand allows IH development.\n- **Orexin Agonists**: Clinicians see complementary role for oxybates in treating nighttime symptoms. LUMRYZ positioned to maintain leadership.\n

Avadel Pharmaceuticals (AVDL)-7 May 25-2025 Q1 Earnings call transcript

- **Market Leadership**: LUMRYZ captures 75% of new oxybate starts, adding 2,500+ patients in 18 months vs. competitor's 833.
- **2025 Growth Plan**: $240M-$260M revenue target (+49%), 40% patient growth, and $20M-$40M cash flow.
- **Clinical Expansion**: IH trial on track for 2026 data, targeting 42,000 undiagnosed patients with no sodium option.
- **Legal Defense**: Fighting for once-nightly innovation with appellate appeal and new patent suits.
- **Operational Efficiency**: 2Q+2025 cash flow positive, adjusted operating income +$1.8M in Q4 2024.


**【CEO Summary Section】**
- LUMRYZ launched in record time, adding over 2,500 net patients in the first 18 months, capturing 75% of new oxybate therapy starts compared to the nearest competitor.
- 2025 strategy focuses on expanding prescriber reach, doubling field support and nurse teams, and enhancing patient education through DTC campaigns.
- IH Phase III trial enrollment on track for 2026 top-line data, with potential to expand oxybate market beyond narcolepsy.
- Legal actions to protect once-nightly dosing innovation, including patent infringement suits and appellate court appeal.

**【CFO Financial Commentary】**
- Q4 2024 net revenue: $50.4M, gross profit: $45.6M (includes 3.5% royalty accrual).
- 2025 revenue guidance: $240M-$260M (49% YoY growth midpoint), cash operating expenses: $180M-$200M.
- Q4 2024 cash flow positive ($8M), ending 2024 with $74M in cash.
- Adjusted operating income positive for two consecutive quarters, targeting $20M-$40M 2025 cash flow.

**【Q&A Key Themes】**
- Sales team expanded by 15% to 53 reps, field support doubled to 28, and nurse team doubled to 28, driving patient pull-through.
- 2025 patient mix tracking above internal expectations, with early signs of switch patient momentum reversal.
- IH trial enrollment on track, with potential NDA filing in 2026 for low/no sodium formulation.
- Litigation updates: appellate court ruling pending, antitrust trial set for November 2025.
- Pediatric indication launch progressing, though small share of total market due to diagnosis delays.


Avadel Pharmaceuticals (AVDL)-3 Mar 25-2024 Q4 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-12 Nov 24-2024 Q3 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-8 Aug 24-2024 Q2 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-8 May 24-2024 Q1 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-4 Mar 24-2023 Q4 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-8 Nov 23-2023 Q3 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-9 Aug 23-2023 Q2 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-9 Nov 22-2022 Q3 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-9 Aug 22-2022 Q2 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-9 May 22-2022 Q1 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-8 Nov 21-2021 Q3 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-9 Aug 21-2021 Q2 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-10 May 21-2021 Q1 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-9 Mar 21-2020 Q4 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-9 Nov 20-2020 Q3 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-10 Aug 20-2020 Q2 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-11 May 20-2020 Q1 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-12 Mar 20-2019 Q4 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-12 Nov 19-2019 Q3 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-9 Aug 19-2019 Q2 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-8 May 19-2019 Q1 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-15 Mar 19-2018 Q4 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-6 Nov 18-2018 Q3 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-7 Aug 18-2018 Q2 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-2 May 18-2018 Q1 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-8 Mar 18-2017 Q4 Earnings call transcript

Avadel Pharmaceuticals (AVDL)-8 Nov 17-2017 Q3 Earnings call transcript

Actual												-0.02	0.49	-0.2	-0.19	-0.23	-0.33	-0.38	-0.45	-1.07	-0.33	-0.48	-0.83	-0.41	-0.32	-0.3	-0.14	-0.03	-0.05	-0.05	0.1
Forecast												-0.2575	-0.1717	-0.245	-0.2557	-0.3156	-0.3122	-0.385	-0.4322	-0.4033	-0.2425	-0.3763	-0.3586	-0.3719	-0.2813	-0.2325	-0.1789	-0.0817	-0.035	-0.075	0.0313
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+92.23%	+385.38%	+18.37%	+25.69%	+27.12%	-5.70%	+1.30%	-4.12%	-165.31%	-36.08%	-27.56%	-131.46%	-10.24%	-13.76%	-29.03%	+21.74%	+63.28%	-42.86%	+33.33%	+219.49%

Actual	--	--	--	--	--	--	--	--	--	--	--	12.24M	10.09M	0	0	0	0	0	0	0	0	0	1.50M	7.01M	19.45M	27.18M	41.50M	50.02M	50.41M	52.51M	68.13M
Forecast	--	--	--	--	--	--	--	--	--	--	--	9.52M	7.92M	0	0	0	0	0	0	0	0	0	361.33K	5.12M	18.19M	25.89M	37.47M	48.43M	50.00M	50.51M	61.40M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+28.60%	+27.48%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+314.02%	+36.86%	+6.96%	+4.96%	+10.77%	+3.28%	+0.82%	+3.96%	+10.96%

AVDL(Delisted)

AVDL fundamentals

AVDL Q2 2025 Earnings

Earnings Call

You can ask Aime